Valeant Appoints ValueAct CEO to Board

Founder and CEO of ValueAct Capital Jeffrey W. Ubben has been appointed to director of the board of Valeant Pharmaceuticals effective October 1, 2014. Ubben has a BA from Duke University and an MBA from Northwestern University. Prior to founding investment company ValueAct Capital in 2000, he was a managing partner at Blum Capital Partners; chairman and director of Martha Stewart Living Omnimedia; and director of Acxiom Corporation.

“Jeff believes in Valeant’s long-term potential, and his expertise and counsel as a committed, long-term Valeant shareholder will be invaluable to me personally, as well as to the entire Board,” said J. Michael Pearson, chairman and CEO of Valeant. “It is incredibly valuable to have such a highly respected firm such as ValueAct, whose focus is on long-term value creation, to be completely aligned with us as we execute our strategy.”

More in News